Clinical Trial Strategy Platform Articles & Analysis
12 news found
The two new business units will use Cellworks’ biosimulation platform and Computational Biology Model (CBM) to predict responses to pharmaceutical interventions in silico, thereby streamlining the clinical trial process by identifying the right patients more rapidly, which in turn reduces the time and expense of developing successful ...
xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma ...
ByxCures
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics targeting the gut-brain axis, today announced the appointment of Fernando Sallés, PhD, as Chief Business Officer. Dr. Sallés joins the Kallyope senior leadership team as the company advances its pioneering drug discovery platform, clinical trials, and pipeline of multiple programs ...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the appointments of George Shiebler as General Counsel and Anita Kawatra as Executive Vice President, Corporate Affairs, to help steer the company as it advances its pioneering drug discovery platform, clinical trials, and pipeline of multiple programs ...
PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter’s new Clinical Workflow Platform, ClinPx. 4D ...
The funds will be used to advance the company’s pioneering drug discovery platform, clinical trials, and pipeline of multiple programs across a broad range of therapeutic areas. ...
Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a new collaboration with “Takeda Pharmaceutical Company Limited ...
Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised €2.5 million in a Series A2 financing round from Sanofi. The funds will be ...
HistoSonics announced today that it has received approval to initiate the company’s second European clinical trial of its new platform technology, which is designed to use the science of histotripsy to mechanically destroy targeted liver tumors, from outside of the body. The study, similar to HistoSonics’ recent FDA approved #HOPE4LIVER U.S. Study, is a multi-center, open label, ...
Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jinko®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with ...
HistoSonics announced today that it has received approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of its new platform technology, which is designed to use the science of histotripsy to mechanically destroy targeted liver tissue and tumors, from outside of the body. The study is a multi-center, open label and single ...
Novadiscovery, a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces that it has strengthened its leadership team with two senior appointments. Jim Bosley has been appointed as Senior Vice President, Modeling and Simulation and Charlotte Turnier has been appointed as Senior Vice President, Sales and ...